Cardiotoxicity with vascular endothelial growth factor inhibitor therapy

Angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) signaling pathway (VSP) have been important additions in the therapy of various cancers, especially renal cell carcinoma and colorectal cancer. Bevazicumab, the first VSP to receive FDA approval in 2004 targeting all cir...

Descripción completa

Detalles Bibliográficos
Autores principales: Touyz, Rhian M., Herrmann, Joerg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988734/
https://www.ncbi.nlm.nih.gov/pubmed/30202791
http://dx.doi.org/10.1038/s41698-018-0056-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988734/
https://www.ncbi.nlm.nih.gov/pubmed/30202791
http://dx.doi.org/10.1038/s41698-018-0056-z

Ejemplares similares